CD274 and non-small cell lung carcinoma: A meta-analysis revealed that the combination of PD-1/PD-L1 inhibitors with RT extended the overall survival of NSCLC patients, simultaneously improving the objective response rate and disease control rate, without increasing the incidence of adverse events above grade 3.